From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 40-49

  Forrer, Flavio ^a   Rolleman, Edgar ^a   Bijster, Magda ^a   Melis, Marleen ^a   Bernard, Bert ^a   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

99mTc DMSA; 177Lu DOTA0,Tyr 3 octreotate; Animal SPECT; PRRT; Renal damage

Indexed keywords

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SUCCIMER; SUCCIMER TC 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MEGADOSE; EX VIVO STUDY; HISTOLOGY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY DISTAL TUBULE; KIDNEY INJURY; KIDNEY TUBULE DISORDER; MALE; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BODY WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, RADIATION; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED LEW; RECEPTORS, PEPTIDE; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34247893931     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.353     Document Type: Article

References (31)

1. 90Y-DOTATOC. J Nucl Med 2002;43:610.
2. 3]octreotate. J Clin Oncol 2004;22:2724.
3. 3]octreotate. Eur J Nucl Med Mol Imag 2003;30:417.
4. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imag 2004;31:1038.
5. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
6. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
7. Forrer F, Uusijarvi H, Waldherr C, et al. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imag 2004;31:1257.
8. 90Y-DOTATOC. J Nucl Med 2005;46:1310.
9. De Jong M, Valkema R, Van Gameren A, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 2004;45:1168.
10. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847.
11. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997;80(Suppl 12.):2591.
12. 3]octreotate in rats. Eur J Nucl Med Mol Imag September 22, 2006.
13. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl 1):115S.
14. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl. 1):67S.
15. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imag 2005;32:601.
16. Uusijarvi H, Bernhardt P, Rosch F, et al. Electron-and positron-emitting radiolanthanides for therapy: Aspects of dosimetry and production. J Nucl Med 2006;47:807.
17. Konijnenberg MW, Bijster M, Krenning EP, et al. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J Nucl Med 2004;45:1260.
18. 99m-Tc dimercaptosuccinic acid renal uptake for an assessment of individual kidney function. J Urol 1978;119:305.
19. 99m-dimercaptosuccinic acid (DMSA): In vitro correlation. J Nucl Med 1979;20:63.
20. Forrer F, Valkema R, Bernard B, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imag 2006;33:1214.
21. 3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319.
22. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imag 2005;32:1136.
23. 3]octreotate. Eur J Nucl Med Mol Imag 2006; (In Press) [Epub ahead of print December 5, 2006.]
24. 111Inoctreotide in mice and rats. J Nucl Med 2006;47:528.
25. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006;47:432.
26. 3]octreotate. [abstract] J Nucl Med 2006;47(Suppl. 1):43P.
27. de Jong M, Barone R, Krenning E, et al. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med 2005;46:1696.
28. Konijnenberg M, Melis M, Valkema R, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134.
29. 3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006;12:897.
30. Jaggi JS, Seshan SV, McDevittMR, et al. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol 2005;16:2677.
31. Jaggi JS, Seshan SV, McDevitt MR, et al. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006;64:1503.